TMD.TO stock opened pre-market at C$1.125, up 2149.99% from the prior close of C$0.05, on 117,220 shares traded. The move makes Titan Medical Inc. (TMD.TO) one of today’s high-volume movers on the TSX in Canada. Volume is 2.55x average and the stock hit a day high of C$1.125 from an open of C$0.05. We break down drivers, valuation, trading metrics, and Meyka AI’s model outlook for traders watching TMD.TO stock today.

TMD.TO stock pre-market volume spike

Titan Medical (TMD.TO) shows abnormal pre-market liquidity with 117,220 shares versus an average daily volume of 45,936. The relative volume of 2.55 signals outsized order flow and rapid repricing. Traders should note the price range moved from a day low of C$0.045 to a day high of C$1.125 in the session.

TMD.TO stock drivers and news context

There is no company press release at the time of this pre-market spike on 04 Mar 2026. The surge follows a tiny float and prior low trading levels — previous close C$0.05 and 50-day average C$0.0734. Such moves often reflect retail interest, short-covering, or a localized catalyst rather than fundamental changes.

TMD.TO stock fundamentals and valuation

Titan Medical reports market cap C$128,295,000 and shares outstanding 114,040,000. Latest quoted EPS is -1.73 and the reported PE metric is not meaningful given negative EPS. Key ratios include a current ratio of 2.78 and cash per share C$0.0667. Revenue per share TTM is C$0.1559, indicating early-stage commercial metrics for this medical-devices company.

TMD.TO stock trading levels and technicals

Price averages are very low: 50-day C$0.0734 and 200-day C$0.0695, making the new price a sharp outlier. Year range is C$0.045–C$1.25. Use tight risk controls: high intraday volatility and a thin bid-ask spread can widen quickly. Watch liquidity near round levels and the day’s volume profile for sustained follow-through.

Meyka AI rates TMD.TO with a score out of 100 and model forecast

Meyka AI rates TMD.TO with a score out of 100: 68.65 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects a 12-month target of C$1.65, implying +46.67% versus the current C$1.125 price. Forecasts are model-based projections and not guarantees.

TMD.TO stock risks and trading strategy

Key risks include limited operating history, negative EPS, and low free float that can magnify moves. For short-term traders, consider scalps with stop losses below recent support. For swing traders, size positions to withstand large intraday swings and monitor news channels and volume confirmation.

Final Thoughts

TMD.TO stock is a high-volume mover in the pre-market session on 04 Mar 2026 after a jump to C$1.125 on 117,220 shares. The price spike looks driven by trading dynamics rather than immediate fundamental releases; EPS remains negative at -1.73 and market cap is C$128,295,000. Meyka AI assigns a 68.65 score (Grade B, HOLD) and the model projects a C$1.65 12-month target, implying an upside of 46.67% from the current price. Traders should treat today’s action as high-risk, watch volume confirmation, and use strict risk controls. For investors focused on fundamentals, wait for clearer commercial progress or corporate updates from Titan Medical before adding exposure. Meyka AI, our AI-powered market analysis platform, will update forecasts if fresh filings or material news appear.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.